Biomedical subjects

A Belić

Publications and source records attributed to A Belić.

At least 19 recordsLinked to original sources

PubMed2005

Asymptotic properties of path integral ideals.

We introduce and analyze an interesting quantity, the path integral ideal, governing the flow of generic discrete theories to the continuum limit and greatly increasing their convergence. The said flow is classified according to the degree of divergence of the potential at spatial infinity. Studying the asymptotic behavior of path integral ideals we isolate the dominant terms in the effective potential that determine the behavior of a generic theory for large discrete time steps.

Journal Article↗

PubMed2005

Systematically accelerated convergence of path integrals.

We present a new analytical method that systematically improves the convergence of path integrals of a generic N-fold discretized theory. Using it we calculate the effective actions S(p) for p< or =9, which lead to the same continuum amplitudes as the starting action, but that converge to that continuum limit as 1/N(p). We checked this derived speedup in convergence by performing Monte Carlo simulations on several different models.

Journal Article↗

PubMed2002

Transport theory of granular swarms.

The transport of trace granular gas (swarm) in a carrier granular fluid is studied by means of the Boltzmann-Lorentz kinetic equation. Time-dependent perturbation theory is used to follow the evolution of the granular swarm from an arbitrary initial distribution. A nonhydrodynamic extension of the diffusion equation is derived, with transport coefficients that are time dependent and implicitly depend on the wave vector. Transport coefficients of any order are obtained as velocity moments of the solutions of the corresponding kinetic equations derived from the Boltzmann-Lorentz equation. For the special case of the initial distribution of swarm particles, transport coefficients are identified as time derivatives of the moments of the number density. Finally the granular particle transport theory is extended by the introduction of the concept of non-particle-conserving collisions.

Journal Article↗

PubMed1996

[Clinical use of hematopoietic growth factors--general principles].

Biology of haematopoietic growth factors in the process of haematopoiesis is well known, but their clinical utilization started with production of recombinant preparations. Today only preparations of Erythropoietin, GM-CSF and G-CSF are commercially at disposal. Absolute indications for utilization of haematopoietic growth factors are states caused by decreased production of certain classes of blood cells as a consequence of shortage of a growth factor necessary for production of a certain class. As these states are very rare, relative indications spread to other states characterized by a decreased number of blood cells or necessity for stimulation of haematopoiesis due to any other reason. This paper contains results of clinical researches only for those growth factors which are not commercially utilized.: M-CSF, Interleukin 3, PIXY321, SCF, Interleukin 6, Interleukin 11, Interleukin 1, Interleukin 2 and Thrombopoietin. Our institution utilizes only the preparations of Erythropoietin (Eprex) and G-CSF (Neuprogen) in 38 patients.

Hematopoiesis↗

PubMed1996

[Clinical use of erythropoietin].

Humoral regulation of erythropoiesis has been known for 100 years, while clinical utilization of recombinant human erythropoietin (rhEPO) only for two decades. It can be said that there is much experience in regard to indications, models and results of its clinical utilization. According to the standpoint of secretion of erythropoietin, anemias can be divided into those where secretion is increased and satisfactory, those where it is increased but not satisfactory and into those where it is not increased or it is even decreased. Anemias of the first group are not an indication for rhEPO utilization, the second group is relative and the third group absolute indication for its utilization. The best results are achieved with absolute indications and it is anemia in chronic renal insufficiency and nonphysiologic anemia of premature babies. Good results can be expected, but not predicted in relative indications, such as anemias in chronic infections, anemias in malignant diseases, myelodysplastic syndrome, aplastic anemia and other secondary anemias. Utilization of rhEPO is useful also in certain states without anemia, especially in transfusiology.

Anemia↗

PubMed1994

[Successful treatment of acquired F:VIII C inhibitor after delivery using plasmapheresis and high doses of immunoglobulins].

Three months after delivery a patient 34 years of age was admitted to the Clinic of haematology in Novi Sad because of sudden massive bleeding from the left ankle, left lower leg as well as for having small haematomas visible at forearms. Examining the mechanism of haemostasis, a diagnosis was made: acquired inhibitor VIII:C coagulation factor. Concentrate of VIII coagulation factor was used in treatment, as well as plasmaphaeresis, high doses of immunoglobulins and immunosuppressive drugs: prednisone and azathioprime. The result was a very quick recovery of the clinical state with loss of inhibitor to VIII: C coagulation factor. Three years after the treatment the patient has no difficulties and no antibodies to VIII:C coagulation factor.

Adult↗

PubMed1994

[Prognosis in patients with myelodysplastic syndromes based on cytomorphologic and clinico-biologic parameters].

Under myelodysplastic syndromes we presume a heterogeneous group of malignant hemopathies with clearly described characteristics of the disease given by a cooperative group of French, American and British authors. Myelodysplastic syndromes most frequently occur at older age. Survival of these patients, after the diagnosis is made, is mostly short because the disease evolves into acute leukemia. Myelodysplastic syndrome is characterized by appearance of refractive anemia, leukemia, thrombocytopenia with signs of expressed dishematopoiesis of the bone marrow. Clear criteria which could define forms with fast or slow course leading to acute leukemia don't exist, so there is a need to group patients into those with good or with bad outcome. The investigation included following parameters important for the outlook of the disease: 1. enlargement of lymph nodes, liver and spleen, 2. biochemical examination of peripheral blood, 3. cytomorphologic changes in the peripheral blood cells and bone marrow. By a follow-up of described parameters a statistically significant influence on survival of the sick concerning the degree of present anemia, absolute number of granulocytes, number of thrombocytes, dishematopoiesis of the peripheral blood and bone marrow, lymphadenomegaly, hepatomegaly and splenomegaly was not found. The percentage of blast in the peripheral blood and bone marrow has a statistically significant influence on patients' short survival.

Adult↗

PubMed1992

[Effect of polychemotherapy in the treatment of patients with non-Hodgkin's lymphoma].

Non-Hodgkin lymphomas belong to malignant hemopathies where clinical course, histological manifestation and therapy response are characterized by diverse features. Sensitivity of the lymphoma to chemotherapy introduced drug combinations for the improvement of patient survival rate and the prognosis. The study reviews the results achieved in 85 patients with NHL treated with different cytostatic combinations (COP, CHOP, COP-BLAM, MEV, LRS-074/B). The majority of the patients (41%) had entered the IV clinical stadium (Ann Arbor) with serious histological types of the disease (LDLL-45% and histiocytic 27%). This made us decide on LRS-074/B protocol (34%) and COP-BLAM cure (20%) planned for those with the advanced clinical stage and poor histological type of the disease. The full remission was achieved in 50%, partial in 28% of the cases while in 20% of the treated patients the therapy response lacked. Relapse of the disease occurs in about 50% of the treated patients. Patients treated with LRS-074/B protocol (p < 0.05) live statistically significantly longer. In a period of 24 months 50% of those treated with LRS-074/B protocol, COP and COP-BLAM cures show no symptoms. There is no a statistically significant difference regarding the mean survival rate (p > 0.05) in relation to the histological type of the disease.

Adult↗

PubMed1992

[Our experiences in the treatment of myelodysplastic syndromes].

From 1987 an abrupt increase of the number of patients presented with MDS has been registered. We present our experiences in the treatment of 42 patients. The number of the male patients was two times larger than of the females. They were most frequently diagnosed as having RAB (43%) and RAEBt (28.5%). RA was found in 14%, RARS in 9.5% and CMML. in only 5% of the cases. The treatment was accomplished with ultralow (3 mg/m2/12h s.c.) and low doses (10 mg/m2/12h s.c.) of ARA-C in 75% of the patients with RAEBt and 44.4% with RAEB, while the CMML group received hydroxyurea. The treatment improved hematologic results but the complete remission lacked. In 23.8% of the cases the disease developed into acute nonlymphoblastic leukemia. Patients excepted from cytostatic therapy were observed by the use of androgens, anabolics, vitamin A+D3 and transfusion of separated erythrocytes. In 38% of the patients with MDS a lethal outcome followed. Life of those in whom the disease developed into acute leukemia in statistically significatly shorter (p < 0.05). There was no statistically significant difference in the survival rate between the treated and nontreated patients (p > 0.05). Further treatment of these patients includes, apart from ultralow doses of ARA-C, the use of retinoic acid, a growth factor (GM-CSF) and bone marrow transplantation.

Adult↗

PubMed1991

[Present possibilities of treatment of chronic B-cell lymphocytic leukemia].

Chronic lymphocytic leukemia (CLL) belongs to the group of diseases with a malignant course and bad outcome. Clinically, the course of CLL exceptionally varies, survival ranges from one to twenty years. The choice of treatment for those affected with CLL is not simple because of the different course of the disease in individual patients and because of the different attitudes in the application of available means of therapy. By introducing antitumor drugs (Interferon alpha-2, Interleukin 2b), new chemotherapeutics (Fludarabin, Pentostatin), monoclonal antibodies and especially by introducing allogenic bone marrow transplantation into therapy, new possibilities are attained for the more efficient treatment of these patients.

Humans↗

PubMed1991

[Prognostic significance of cytologic and histomorphologic changes in bone marrow in the treatment of patients with chronic lymphocytic leukemia].

In the aim of establishing the prognosis of chronic lymphocytic leukemia (HLL) in relation to the severeness and course of the disease, during the course of treatment of the patients, two parameters were followed prior to therapy and one year following conducted therapy regarding the morphological changes of lymphocytes in bone marrow specimens and peripheral blood samples and the type of cell infiltration in the bone marrow by means of histomorphological examination. The obtained results point to the fact that progression of illness can be expected also in those patients who are in a milder clinical stadium (stadium A), in the cases when we find more than 20% of atypical lymphocyte forms (prolymphocytes and forms with nucleus aberrations) in the peripheral blood and in the bone marrow, as well as in the cases with a diffuse type of bone marrow infiltration. Such forms should be checked more often. At the same time application of therapy is suggested right after the diagnosis is set, even though the patient may be in the early clinical stadium of the disease, as well as the decision about aggressive treatment.

Aged↗

PubMed1989

[Experience in the ambulatory care of patients with hematologic diseases at the Hematology Day Hospital].

Upon establishing new out-patient services at the Clinical Centre, Clinic of Hematology has set up a new diagnostic and therapeutic department which is popularly named "Hematologic Daily Hospital". In way, the work at the Clinic of Hematology has been completely changed, since a new activity in the out-patient management of hematologic patients has been initiated. In the course of 8-hour working time numerous various diagnostic and therapeutic interventions are being performed in "Hematologic Daily Hospital", such as: a detailed survey of the patients, biologic material is taken and sent to various analyses, sternal and other functions are performed, cytologic analyses of punctates obtained, patients are referred to radiologic, ultrasonographic, CT and other surveys, administration of parenteral therapy of corresponding solution with or without cytostatics, blood and blood derivate transfusion as well as the application of various forms of apheresis. Data on the number and kinds of services applied are presented in this paper with the insight on the organization of work. Such an organization of work has made diagnostic of hematologic patients faster and has contributed to a simpler employment of therapy.

Ambulatory Care↗

PubMed1989

[Clinical evolution of chronic lymphocytic leukemia in Richter's syndrome].

Over a few year period chronic lymphocytic leukemia (CLL) is mainly characterized by stable course and only in the small per cent of patients it evolves into the aggressive form. Richter's syndrome has been diagnosed at our clinic in a patient who was for 6 years controlled and treated for CLL. In that period the patient was doing well and the out-patient treatment of CLL was being performed together with regular check-ups according to hematologic findings and clinical status of the patient. The patient was capable of work. Clinical investigation was undertaken because of the sudden aggravation of the general state and x-ray of the chest which pointed to the existence of tumorous shadow in the right lower pole of hilus. Although a complete CLL remission was established cytologic diagnosis of the newly formed tumour pointed to non-Hodgkin lymphoma of high malignity (centroblast lymphoma). Course of disease was terminated lethally very soon, because lymphoma of high malignity did not respond to polychemotherapy.

Humans↗

PubMed1987